Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Adult Acute Lymphoblastic Leukemia: early-phase trial registry
1 of 9 indexed Recurrent Adult Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Recurrent Adult Acute Lymphoblastic Leukemia: 9 US clinical trials tracked, 1 recruiting.
Recurrent Adult Acute Lymphoblastic Leukemia is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-adult-acute-lymphoblastic-leukemia
OPEN 1 | RECR 11% | LATE 0 | EARLY 9 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)
Recurrent Adult Acute Lymphoblastic Leukemia lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Adult Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Adult Acute Lymphoblastic Leukemia is recruiting below its size-band peers.
1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Adult Acute Lymphoblastic Leukemia research.
National Cancer Institute (NCI) accounts for 4 of 9 trials (44.4%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Adult Acute Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
Recurrent Adult Acute Lymphoblastic Leukemia research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
NCT02333162
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
City of Hope Medical Center
NCT02094794
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT00792948
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
NCT03241940
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00918333
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
National Cancer Institute (NCI)
NCT00084916
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
SWOG Cancer Research Network
NCT01925131
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
National Cancer Institute (NCI)
NCT01132573
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02484430
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Adult Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Adult Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Adult Acute Lymphoblastic Leukemia page
9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Adult Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Adult Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Adult Acute Lymphoblastic Leukemia condition card totals 9 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.